Entry into a Material Definitive Agreement
Show detailsHide details
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Relay Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that designs small-molecule medicines by studying how proteins move and change shape, using its Dynamo platform to create "movies" of protein motion rather than static snapshots. Founded in 2015 as Allostery, Inc., it was renamed Relay Therapeutics to reflect that focus on protein motion, and its lead drug candidate targets a common mutation in breast cancer.
1.01 Entry into a Material Definitive Agreement · 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 5.07 Submission of Matters to a Vote of Security Holders · 9.01 Financial Statements and Exhibits
1.01 Entry into a Material Definitive Agreement · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · 9.01 Financial Statements and Exhibits